Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: Up-regulation by interleukin-1β and glucocorticoids

Arthritis and Rheumatism

Volumn 50, Issue 10, 2004, Pages 3118-3128

  Toh, Myew Ling ^a   Yang, Yuan ^a   Leech, Michelle ^a   Santos, Lanie ^a   Morand, Eric F ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DEXAMETHASONE; GLUCOCORTICOID; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FETAL CALF SERUM; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; UPREGULATION; WESTERN BLOTTING;

ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CELLS, CULTURED; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-1; MIFEPRISTONE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE-PHOSPHATASE; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 5644230846     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20580     Document Type: Article

References (49)

1. Firestein G, Manning A. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999;42:609-21.
2. Mitchell R, Metz C, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999;274:18100-6.
3. Theodosiou A, Ashworth A. MAP kinase phosphatases. Genome Biol 2002;3:3009.1-10.
4. Schliess F, Heinrich S, Haussinger D. Hyperosmotic induction of the mitogen-activated protein kinase phosphatase MKP-1 in H411E rat hepatoma cells. Arch Biochem Biophys 1998;351:35-40.
5. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002;22:7802-11.
6. Brondello JM, Brunet A, Pouyssegur J, Mckenzie F. The dual specificity mitogen-activated protein kinase phosphatase-1 and-2 are induced by the p42/p44MAPK cascade. J Biol Chem 1997;272:1368-76.
7. Franklin CC, Kraft AS. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem 1997;272:16917-23.
8. Slack DN, Seternes OM, Gabrielsen M, Keyse SM. Distinct binding determinants for ERK2/p38a and JNK MAP kinases mediate catalytic activation and substrate selectivity of MAP kinase phosphatase-1. J Biol Chem 2001;276:16491-500.
9. Firestein G. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum 1996;39:1781-90.
10. Schett G, Tohidast-Akrad M, Smolen J, Schmid B, Steiner C, Bitzan P, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43:2501-12.
11. Suzuki M, Tetsuka S, Watanabe N, Kobayashi M, Matsui N, Takashi O. The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-α or IL-1β-stimulated rheumatoid synovial fibroblasts. FEBS Lett 2000;465:23-7.
12. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al. c-jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73-81.
13. Lacey D, Sampey A, Mitchell R, Bucala R, Santos L, Leech M, et al. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum 2003;48:103-9.
14. Barchowsky A, Frleta D, Vincenti MP. Integration of the NF-KB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine 2000;12:1469-79.
15. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato A. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001;20:7108-16.
16. Imasato A, Desbois-Mouthon C, Han J, Kai H, Cato AC, Akira S, et al. Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of Toll-like receptor 2. J Biol Chem 2002;277:47444-50.
17. Engelbrecht Y, de Wet H, Horsch K, Langeveldt C, Hough F, Hulley P. Glucocorticoids induce rapid up-regulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines. Endocrinology 2003;144:412-22.
18. Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
19. Alessi D, Cuenda A, Cohen P, Dudley D, Saltiel A. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94.
20. Lee J, Laydon J, McDonnell P, Gallagher T, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46.
21. Bennett B, Sasaki D, Murray B, O'Leary E, Sakata S, Xu W, et al. SP600125, an anthrapyrazolone inhibitor of jun N-terminal kinase. Proc Natl Acad Sci U S A 2001;98:13681-6.
22. Yuan Y, Morand E, Getting S, Paul-Clark M, Liu D, Yona S, et al. Modulation of inflammation and response to dexamethasone by annexin 1 in antigen-induced arthritis. Arthritis Rheum 1994;50:976-84.
23. Badger A, Griswold D, Kapadia R, Blake S, Swift BA, Hoffman SJ, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43:175-83.
24. Miyazawa K, Mori A, Miyata H, Akahane M, Ajisawa Y, Okudaira H. Regulation of interleukin-1β-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. J Biol Chem 1998;273:24832-8.
25. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59 Suppl 1:i21-7.
26. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
27. Amano Y, Lee SW, Allison AC. Inhibition by glucocorticoids of the formation of interleukin-1α, interleukin-1β, and interleukin-6 mediation by decreased mRNA stability. Mol Pharmacol 1993;43:176-82.
28. Tobler AR, Meier R, Seitz M, Dewald B, Baggiolini M, Fey MF. Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8 and IL-6, but not of M-CSF in human fibroblasts. Blood 1992;79:45-51.
29. Luo G, Hershko DD, Robb BW, Wray CJ, Hasselgren P. IL-1β stimulates IL-6 production in cultured skeletal muscle cells through activation of MAP kinase signaling pathway and NF-KB. Am J Physiol Regul Integr Comp Physiol 2003;284:R1249-54.
30. Nishitai G, Shimizu N, Negishi T, Kishimoto H, Nakagawa K, Kitagawa D, et al. Stress induces mitochondria-mediated apoptosis independent of SAPK/JNK activation in embryonic stem cells. J Biol Chem 2004;279:1621-6.
31. Huang Q, Yang J, Walker C, Cheng J, Liu Z, Su B. Differential regulation of interleukin 1 receptor and toll-like receptor signaling by MEKK3. Nat Immunol 2004;5:98-103.
32. Beltman J, McCormick F, Cook SJ. The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-jun expression, and activates jun N-terminal kinase. J Biol Chem 1996;271:27018-24.
33. Guo YL, Kang B, Williamson J. Resistance to TNF-α cytotoxicity can be achieved through different signaling pathways in rat mesangial cells. Am J Physiol 1999;276:C435-41.
34. Guo YL, Kang B, Williamson J. Inhibition of the expression of mitogen-activated protein phoshatase-1 potentiates apoptosis induced by tumour necrosis factor-α in rat mesangial cells. J Biol Chem 1998;273:10362-6.
35. Geng Y, Valbracht J, Lotz M. Selective activation of the mitogen activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. J Clin Invest 1996;98:2425-30.
36. Pillinger M, Rosenthal P, Tolani S, Apsel B, Dinsell V, Greenberg J, et al. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol 2003;171:6080-9.
37. Chen P, Li JD, Barnes J, Kokkonen G, Lee J, Liu Y. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 2002;169:6408-16.
38. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato A. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001;20:7108-16.
39. Lim HW, New L, Han J, Molkentin JD. Calcineurin enhances MAPK phosphatase-1 expression and p38 MAPK inactivation in cardiac myocytes. J Biol Chem 2001;276:24832-8.
40. Moreland LW, O'Dell JR. Glucocorticoids and rheumatoid arthritis. Arthritis Rheum 2002;46:2553-63.
41. Yang YH, Hutchinson P, Leech M, Morand EF. Exacerbation of adjuvant arthritis by adrenalectomy is associated with reduced leukocyte lipocortin 1. J Rheumatol 1997;24:1758-64.
42. Barnes P. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998;94:557-72.
43. Lehmann T, Murphy C, Zahra D, Handel M. Reduction of tumor necrosis factor induced nuclear factor-KB nuclear translocation and DNA binding by dexamethasone in human osteoarthritic synovial tissue explants. J Rheumatol 2002;29:787-95.
44. Han CW, Coi JH, Kim JM, Lee KY, Oh GT. Glucocorticoid-mediated repression of inflammatory cytokine production in fibroblast-like synoviocytes is independent of nuclear factor-KB activation induced by tumour necrosis factor α. Rheumatology 2001;40:267-73.
45. Noguchi T, Metz R, Chen L, Mattel MG, Carrasco D, Bravo R. Structure, mapping, and expression of erp, a growth factor inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth. Mol Cell Biol 1993;13:5195-205.
46. Arts GJ, Langemeijer E, Tissingh R, Libin M, Pavliska H, Dokic K, et al. Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res 2003;13:2325-32.
47. Zhang H, Hyde K, Page G, Brand J, Zhou J, Yu S, et al. Novel tumour necrosis factor α-regulated genes in rheumatoid arthritis. Arthritis Rheum 2004;50:420-31.
48. Orlowski RZ, Small GW, Shi YY. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 2002;277:27864-71.
49. Dorfman K, Carrasco D, Gruda M, Ryan C, Lira S, Bravo R. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 1996;13:925-31.